A phase II study of ZD6474 (Zactima, a selective inhibitor of VEGFR and EGFR tyrosine kinase in patients with relapsed multiple myeloma--NCIC CTG IND.145.

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples